The Medical Letter on Drugs and Therapeutics
Genvoya - A New 4-Drug Combination for HIV
February 15, 2016 (Issue: 1488)The FDA has approved Genvoya (Gilead), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) elvitegravir, the pharmacokinetic enhancer cobicistat, and the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)...more
- A 4-drug combination (Stribild) for HIV. Med Lett Drugs Ther 2012; 54:95.
- Panel of Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: aidsinfo.nih.gov. Accessed February 4, 2016.
- HHS Panel on Antiretroviral Guidelines for Adults and Adolescents includes a fixed-dose combination of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide among the recommended regimens for antiretroviral treatment-naive Individuals with HIV-1 infection. November 18, 2015. Available at: aidsinfo.nih.gov. Accessed February 4, 2016.
- Drugs for HIV infection. Treat Guidel Med Lett 2014; 12:7.
- PE Sax et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015; 385:2606.
- D Wohl et al. A randomized, double-blind comparison of tenofovir alafenamide (TAF) vs. tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr 2016 January 29 (epub).
- A Mills et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 2016; 16:43.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2013; 55:e44.
- S Fourati et al. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. J Antimicrob Chemother 2015; 70:1507.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.